\
&
Contact us
\
&
Contact us
Starts in 1 month from now
LocationBrussels, Belgium
This event is organised by the Flemish knowledge center for citizen science Scivil, the EU-funded project European Citizen Science (ECS) and the European Citizen Science Association (ECSA).
The fair offers an opportunity to present research in an interactive way, allowing visitors to learn more about the research itself while experiencing the importance of citizen science firsthand. The organisation will handle communication with the press, schools, SciComm partners, and European institutions to reach a broad and diverse audience.
Highlights from the Citizen Science Fair will be presented at the Cluster Event “Advancing Public Engagement and Citizen Science in the European Research Area” on 19 June. This event brings together policymakers and citizen science projects to strengthen the impact of public engagement in research.
Anyone interested to present their project(s) could sign up by 21 March using the form which is made available in the announcement on the Scivil website. For questions about the fair: info@scivil.be.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
